Full Press Release Details
to Present at BIO-Europe Spring 2018 Conference
with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented
acquired resistance and reversed resistance of colon, lung and head-and-neck cancers in patient-derived xenograft models
Aviv, Israel, March 8, 2018 - Kitov Pharmaceuticals
(NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that Dr. Gil Ben-Menachem, VP Business Development
of TyrNovo, a Kitov Pharmaceuticals company, will present recent results from pre-clinical studies with NT219, a novel dual inhibitor
of STAT3 and IRS1/2, at the 2018 BIO-Europe Spring Conference at the RAI Convention
Center, in Amsterdam, The Netherlands.
is an innovative, unique small molecule targeting IRS1/2 and STAT, two signal proteins that are part of an anti-cancer drug
resistance mechanism. In various preclinical models where NT219 was administered in combination with various oncology
therapies, outstanding efficacy in preventing acquired resistance and reversing tumor resistance was
on the presentation are as follows:
Dr. Gil Ben-Menachem
Date and Time: Tuesday, 13 March, 2018, 4:45 PM
Room E105, RAI Convention Center
Spring is a registered trademark
of EBD Group AG and the Biotechnology Industry Organization
is a small molecule that presents a new concept in cancer therapy by promoting the degradation and the phosphorylation of two
oncology-related checkpoints, Insulin Receptor Substrates (IRS) 1 and signal transducer and activator of transcription 3 (STAT3),
respectively. While targeted anti-cancer drugs inhibit the "ON" signal, NT219 activates the "OFF" switch,
extensively blocking major oncogenic pathways. In pre-clinical trials, NT219, in combination with several approved cancer drugs,
displayed potent anti-tumor effects and increased survival in various cancers, including sarcoma, melanoma, pancreatic, lung,
ovarian, head & neck, prostate and colon cancers, by preventing the tumors from developing drug resistance and reversing resistance
after it has been acquired.
Ltd., a Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) company, is a developer of novel small molecules in the oncology therapeutic
field. TyrNovo is developing NT219, an oncology product designed to be used in combination with other oncology drugs. NT219 is
a small molecule that presents a new concept in cancer therapy. In combination with various approved oncology drugs, NT219 has
demonstrated potent anti-tumor effects and increased survival in various cancer models, including sarcoma, melanoma, pancreatic,
lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is through the prevention of acquired resistance
in tumors and by regression of resistant tumors. For more information on TyrNovo please visit http://www.tyrnovopharma.com.
Kitov Pharmaceuticals
Pharmaceuticals (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development group of companies.
Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare and business professionals maintains
a proven track record in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, Consensi ,
intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoints for its Phase III
and Phase III/IV clinical trials. NT219, which is developed by its majority-owned subsidiary TyrNovo Ltd., is a novel patented
small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development
risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term
potential to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content of which
is not part of this press release, please visit http://www.kitovpharma.com.
Statements and Kitov's Safe Harbor Statement
statements in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by
the use of forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue
reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect
our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve
known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual
results, performance or achievements to be significantly different from any future results, performance or achievements expressed
or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among
others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process with
uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress
and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in
regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals
necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration
or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and
regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products
once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence
on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend
issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail,
obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation,
and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical
public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial
and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and
other factors that are discussed in our in our Annual Report on Form 20-F for the year ended December 31, 2017 and in our other
filings with the SEC, including our cautionary discussion of risks and uncertainties under 'Risk Factors' in our Registration
Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected
results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press
release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any
forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise,
except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to
the SEC, which are available on the SEC's website, http://www.sec.gov
further information, contact:
Financial Officer of Kitov and Director of TyrNovo